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Editorial
Haematopoietic and lymphoid neoplasms like
lymphomas and leukemias are common occurrences
both among adults and children. Fortunately, a
significant number of these disorders are curable
with modern chemotherapeutic regimen. First step
is a precise laboratory diagnoses using modern
diagnostic tools. Besides routine morphology
diagnoses of these disorders has been revolutionized
by immunological and genetic analyses. Quick
transfer of modern tools from research lab to
diagnostic lab and then to bedside is unprecedented
and unmatched by developments in any other organ
system. Indeed they are the bench mark from where
a lot needs to be learnt by others.

physical resources. For example, a comprehensive
‘Immunohistochemical’, ‘Flow Cytometric’ and
‘Cytogenetic ‘ facility along with highly qualified
and dedicated faculty to ensure precise diagnoses
of these disorders from where begins the proper
treatment of the patient follows.
In this issue we have mainly focused on the
diagnostics of tumour screening and highlighted new
tumour markers.
Dr Shahid Pervez,
Professor & Consultant Histopathology,
Department of Pathology & Microbiology,
Aga Khan University Hospital,

The Aga Khan University Hospital Clinical
Laboratory is equipped with required human and

Immunophenotyping by Flowcytometry
Sidra Asad Ali
Haematology

Introduction

History

Over the past few years, the role of flowcytometry
in haematology especially in malignant
haematology has become inevitable. It has made
a transition from being an experimental device
of colossal magnitude confined to research
laboratories, into a bench-top instrument of
indispensible use in the diagnosis, classification and
monitoring disease response.

The original flowcytometer was the Coulter
counter (Beckman Coulter M) invented by
Wallace Coulter in the 1950s. It was in
1968, when the first fluorescence-based flow
cytometry device (ICP 11) was developed
by Wolfgang Göhde from the University of
Münster, Germany and later commercialized
by German developer and manufacturer Partec
through Phywe AG in Göttingen. After a decade,
in 1978, at the Conference of the American
Engineering Foundation in Pensacola, Florida,
the name flowcytometry was given to this
methodology. Before that it was known as pulse
cytophotometry.

Definition
The word ‘cyto’ means cell and ‘metry’ is
measurement. So flowcytometry is measuring
properties of cells in a flowing system. It evaluates
optical and fluorescent characteristics of a cell or
any other particle such as nuclei, microorganisms,
chromosome preparations and latex beads.
When a fluorescent dye is conjugated to a
monoclonal antibody, it can be used to identify a
particular cell type based on the individual antigenic
surface markers of the cell.

Advancement in the field of immunophenotyping
by flowcytometry with the availability of a wide
variety of antibodies and flourochromes
(a fluorescent chemical compound that can
re-emit light upon light excitation) has led to
more accurate and precise identification
of cells.
3
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Principle
A beam of monochromatic light, usually from laser,
intersects cells which are hydrodynamically-focused
and are allowed to pass one by one through the point
of interrogation. As soon as the interaction occurs,
light is emitted in all directions and captured via
detectors that direct the light to a series of filters and
dichroic mirrors that isolate particular wavelength
bands. These light signals are then detected by
photomultiplier tubes and computerized for further
analysis.
There are number of detectors that are placed at
different points where the stream passes through the
light beam. The one which is placed in line with the
light beam is called forward side scatter and those
placed perpendicular to light beam are known as side
scatter. There are multiple fluorescence emission
detectors as well which are placed at different positions.
Fluorochrome
It is a fluorescent dye is conjugated monoclonal
antibodies, which then bind to specific proteins

(antigens) present on the surface, cytoplasm or
nucleus of the cell. When these flourochome labeled
cells are passed through a light beam, the fluorescent
molecules absorbs light and caused the electrons to
get into higher energy state. This excited electron
quickly decays into a ground state or resting state
and emit excess energy at a higher wave length. This
transition of energy by different flourochromes allow
multiple characteristics of the cells to be measured
including cell size, cytoplasmic content, complexity,
DNA or RNA properties, variety of membrane and
intracellular proteins.
Propidium iodide, phycoerythrin, and fluorescein are
the dyes which are commonly used. Tandem dyes
with internal fluorescence resonance energy transfer
can create even longer wavelengths and more colors.
Specimen
Flowcytometry is used for immunophenotyping of a
variety of specimens, including whole blood, bone
marrow aspirate, serous cavity fluids, cerebrospinal
fluid, urine, fine needle aspiration and biopsies of
lymph node and from other lymphoid tissues.

Table:1 Applications of Flowcytometry:

Field

Clinical application

Common characteristic measured

Hematology

Leukemia and lymphoma phenotyping
Identification of prognostically important
subgroups
Hematopoietic progenitor cell enumeration
Diagnosis of systemic mastocytosis
Reticulocyte enumeration
Hereditary Spherocytosis

Leukocyte surface antigens
TdT, MPO

Autoimmune and alloimmune disorders
Anti-platelet antibodies
Anti-neutrophil antibodies
Immune complexes
Feto-maternal hemorrhage quantification
Immunology
Histocompatibility cross-matching
Transplantation rejection
HLA-B27 detection
Immunodeficiency studies
Oncology
DNA content and S phase of tumours
Measurement of proliferation markers
Blood banking
Immunohematology
Assessment of leukocyte contamination of
blood products
PNH
Genetic disorders Leukocyte adhesion deficiencya

CD34
CD25, CD69
RNA
Eosin-5′-maleimide-labeled intact red blood
cells
IgG, IgM
IgG
Complement, IgG
Hemoglobin F, rhesus D
IgG, IgM
CD3, circulating OKT3
HLA-B27
CD4, CD8
DNA
Ki-67, PCNA
Erythrocyte surface antigens
Forward and side scatter, leukocyte surface
antigens
CD55, CD59
CD11/CD18 complex

Ref: Flow Cytometry: Principles and Clinical Applications in Hematology. Clinical Chemistry. August 2000 vol. 46 no. 8 1221-1229
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Immunophenotyping of Hematological
Malignancies

automated multidimensional visualization as well as
post-analysis data aggregation models.

The use of flowcytometry in haematological
malignancies has a pertinent role. To begin with, only
a restricted panel of monoclonal antibodies were used
and it was largely focused on further characterization
and determining the lineage (lymphoid versus
myeloid origin of blast cells in acute leukemia)
after the diagnosis of leukemia/lymphoma. Over the
period of time, an extensive range of flourchomes
have been developed and it is now used not only for
diagnosis and classification but also for assessing
prognosis, response of disease and for determining
minimal residual disease with the help of individual
immunophenotypic markers.

Future Directions

Limitations
Presence of particles in single-cell suspension only
and properties of the fluorescent molecules used to
stain the cells and photon statistics of fluorescence
from the stained and unstained populations of cells
are the few drawbacks of the methodology. Lack of
standardization in and instrument set-up and assay is
major limitation. Attention has been given and lot of
efforts has been done to introduce standard protocols.
Another limitation is subjectivity of the operator
who gates the specific population, as the substantial
amount of information generated which makes
interpretation intricate. An important advancement
in this regard is the development of gating tools,

There have been a lot of advancements which has
improved the instrument, conjugated antibodies
and the software. Image cytometry is the recent
progress, which has combined modern multicolor
flowcytometry with microscopy or transcripational
profiling.
Cytometry by mass cytometer, utilizes time-offlight mass spectrometry to discriminate a set of
more than 40 heavy metal ion–labeled antibodies
without the shortcomings of fluorescence spillover
or autofluorescence (Bendall et al., 2011, 2012). The
Fludigm Biomark system allows the quantification
of mRNA levels using highly multiplexed realtime PCR using special microfluidic devices, thus
allowing detection of up to more than 100 gene
transcripts from a single cell.
Summary
Flowcytometer is a powerful tool for measuring
multiple characteristics of a single cell. With the
progression into smaller, user friendly and less
expensive device and with also introduction of wide
variety of antibodies, the use of flowcytometer has
become ineluctable in the diagnosis and management
of broad spectrum of diseases.

Chronic Lymphocytic Leukaemia: Diagnosis
and Prognostic Factors
Dr Farheen Karim
Haematology

Chronic lymphocytic leukaemia (CLL) is a chronic
B-cell lymphoproliferative disorder. It is more
prevalent in the western population and is the
most common type of leukaemia in the west. CLL
is more commonly seen in men and in the
elderly.
Diagnosis
Most of the patients with CLL are diagnosed
incidentally based on lymphocytosis on a

complete blood count. However, some patients
may present with lymphadenopathy, systemic
symptoms such as fever, night sweats and
weight loss or the symptoms of anemia or
infection.
The diagnosis of CLL requires presence of >5
x 109/l circulating clonal B lymphocytes with
characteristic morphology persisting for >3 months
and a characteristic immunophenotype detected by
flow cytometry.
5
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Morphologically, lymphocytes in CLL are small
in size with scanty cytoplasm. The nucleus shows
clumped chromatin and the nucleolus is not visible.
There is also presence of many smear or smudge
cells on the peripheral film (as shown in Figure 1).

to define complete response after treatment.
It is also indicated in determining the cause
of cytopenias and assessing the pattern of
involvement by the lymphoid cells (diffuse,
nodular or interstitial).
Lymph node biopsy is only indicated when there is
diagnostic uncertainty or clinical suspicion of
lymphomatous transformation known as Ritcher’s
transformation.
Prognosis

Figure 1: Peripheral film of a patient with CLL showing lymphocytosis
and smear cells (AKUH Lab)

Immunophenotyping shows expression of
CD19, CD20, CD23 and CD5. There is weak
expression of surface membrane immunoglobulin
with light chain restriction i.e. only a single
immunoglobulin light chain ( kappa or lambda)
is expressed not both, confirming the clonal
nature of these cells. Additionally, CLL cells are
usually negative for cyclin D1 and CD10. FMC7,
CD22, and CD79b are also commonly negative or
weakly expressed.
Bone marrow examination is not essential
for the diagnosis of CLL, but is mandatory

The various factors that predict poor prognosis in
CLL include the following:

Advanced stage of disease (Binet B and C and
Rai II and IV)

Diffuse pattern of bone marrow infiltration

No response to treatment

Male sex

Unmutated Immunoglobulin heavy chain (IgVH)

High Zap-70 and CD 38 expression detected by
flow cytometry

High LDH and Beta-2 microglobulin levels

P53 or deletion 17p detected by FISH has the
worst prognosis. Detection of 11q23 deletions
and trisomy 12 is also a bad prognostic marker.
Presence of 13qDel as a sole abnormality confers
a good prognosis.

Rapid lymphocyte doubling time
Detection of these prognostic factors can
help in predicting the course of illness in a
patient.

Tumour Markers
Dr Syed Talha Naeem
Chemical Pathology

Introduction
Current clinical practice has a growing impetus on early
diagnosis, proper prognostication and screening for
malignancy in asymptomatic groups. Tumour markers
are assuming a growing role in all aspects of cancer care,
starting from screening to follow-up after treatment.
These markers are a structurally and functionally diverse
group which includes amines, glycoproteins, hormones,
enzymes, paraproteins and tumour associated antigens
found in the blood, urine or tissues of patients with
6

certain types of cancer. They are typically produced by
tumour cells, but in some cases they may be produced
by the body in response to malignancy or to certain
benign conditions. Tumour markers are not elevated in
all cancer patients, particularly patients with early-stage
cancer. They are measured qualitatively or quantitatively
by chemical, immunological, or molecular biological
methods. The characteristics of an ideal tumour marker
are shown in Table 1.
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Table 1: Characteristics of an Ideal Tumour Marker

Characteristics
Highly specific
Highly sensitive
Long lead-time
Levels correlate with tumour burden
Short half-life
Simple and cheap test
Easily obtainable specimens
How are Tumour Markers Used?
Clinical uses can be broadly classified into 4 groups.
1. Screening and early detection: Screening
refers to testing for cancer in people who have no
symptoms of the disease. Early detection is finding
cancer at an early stage, when it’s less likely to have
spread and is easier to treat. Tumour markers were
first developed to screen for cancer – to look for
cancer in people without symptoms – but very few
markers have been shown to be helpful in this way.
A perfect tumour marker would be one that could be
used as a cancer screening blood test for all people.
The tumour marker would only be elevated in people
with cancer. At this time there are no tumour marker
tests that work like this.
2. Diagnostic confirmation: By and large, tumour
markers cannot be construed as primary modalities
for the diagnosis of cancer, mainly because of the
lack of sufficiently high specificity and sensitivity.
Their main clinical utility is as a laboratory test to
support the diagnosis or in follow-up of patients
being treated for malignancy. Attempts to improve
the sensitivity and/ or specificity of tumour markers
have led to combination of tumour markers with
other procedures (e.g., combination of Carbohydrate
antigen (CA) 125 with ultrasonography for early
detection of ovarian malignancy) or to refining the
evaluation criteria for tumour markers (e.g., PSA
density or PSA velocity or age-specific PSA cut off
ranges for early detection of prostate cancer).
3. Prognosis and prediction of therapeutic
response: Tumour marker levels, in certain
situations, reflect tumour burden in the body and
hence can be used in staging, prognostication or
prediction of response to therapy. Markers usually

Remarks
Detectable only in one tumour type
Non-detectable in physiological or benign disease
states
Sufficient time for alteration of natural course of
disease
Prognostic and predictive utility of the tumour marker
Frequent serial monitoring of the marker levels after
5-6 half lives
Applicability as screening test
Acceptability by target population
increase with progressive disease, decrease with
remission and do not change significantly with stable
disease. Tumour marker kinetics is generally more
important than individual values.
4. Monitoring disease and recurrence:
Monitoring disease is, perhaps, the most common
clinical use of serum tumour markers. Rising
trend in serum levels may detect recurrence of
disease well before any clinical or radiological
evidence of disease is apparent (“biochemical
recurrence”).
When are Tumour Markers Measured?
It is imperative to remember that though an
aggressive investigative approach may be warranted
on the basis of raised tumour marker values,
treatment cannot be initiated without undisputable
documentation (often histological) of the disease.
A single value or test is unreliable in itself. It is
noteworthy that in most situations, elevations of
markers in nonmalignant diseases are often transient,
whereas elevations associated with cancer either
remain constant or continuously rise. Ordering serial
testing can help detect falsely elevated levels due to
transient elevation.
Knowledge of the assay method is important in
interpretation of either an abnormal value or a serial
change in tumour marker values. Various methods of
detection have their own specific cut off values and
sensitivities. Thus, for any set of serial values to be
meaningful, they have to come from the same assay
methods and preferably from the same laboratory.
In certain situations of so-called biochemical
recurrences, it is always useful to go back to the
laboratory to confirm this. In tumours with multiple
raised markers measured prior to definitive therapy,
7

VOL. 39, ISSUE 1

SEPTEMBER 2013
Table 2: Tumour markers tested in the section of Chemical Pathology, AKUH

Marker

Malignancy

Nonmalignant conditions

Alpha fetoprotein
(AFP)

Hepatoma, Germ cell tumours

Viral hepatitis, liver injury, inflammatory bowel
disease, pregnancy

β-hCG

Choriocarcinoma, Germ cell
tumours

Testicular failure, marijuana smokers, pregnancy

Carcinoembryonic
antigen (CEA)

Colorectal, stomach, pancreas

Smokers, inflammatory bowel disease, hepatitis,
cirrhosis, pancreatitis, gastritis

CA 125

Ovarian

Peritoneal irritation, endometriosis, pelvic inflammatory disease, hepatitis, pregnancy

PSA

Prostate

Prostatitis, benign prostatic hyperplasia

CA 15-3

Breast

Liver cirrhosis, tuberculosis, sarcoidosis, benign
breast disease, pelvic inflammatory disease,
endometriosis, systemic lupus erythematosus,
lactation and pregnancy

CA 19-9

Colorectal, stomach, pancreas

Biliary tract obstruction, cholangitis, inflammatory
bowel disease, acute or chronic pancreatitis, liver
cirrhosis, cystic fibrosis, thyroid disease

Calcitonin

Thyroid (Medullary carcinoma)

-

Beta-2microglobulin

Myeloma, chronic lymphocytic
leukemia (CLL), and some
lymphomas (including
Waldenstrom macroglobulinemia)

Thyroglobulin

Thyroid (papillary, follicular)

the marker showing highest elevation should be used
for follow-up.
Tumour marker kinetics should always be factored
before repeating the tests. Too frequent estimation
of the tumour marker may misrepresent the course
of the disease due to distribution and elimination
kinetics. As a general guideline, the time interval
between serial determinations should be three
months; but in case of an abnormal value, a repeat
estimate can be ordered within two to four weeks
irrespective of the initial reading.
The success of surgical removal of a tumour as
determined by tumour marker concentrations is
ideally ascertained after a period not less than 5-6
8

Kidney disease and hepatitis
half-lives, to allow tumour marker levels to make a
plateau or fall to normal. This period may be even
longer in case of treatment with chemotherapy
or radiotherapy, wherein the therapeutic effects
themselves are manifested after a lag period.
Patient characteristics affect the tumour marker
values to a significant degree. The anticipated fall
in levels may not be evident in situations where the
metabolism or excretion of the tumour marker is
altered, like in patients with renal or liver disease,
depending on whether the tumour marker is removed
through glomerular filtration or metabolized by the
liver. For example, serum CEA is often elevated in
patients with liver diseases because the metabolism
of CEA by the diseased liver is subnormal. False
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tumour marker elevation is also known to occur in
other confounding situations like smoking, ethanol
consumption, COPD, etc., especially if there has
been a recent change in habits.
Usually multiple tumour markers are associated
with individual malignancy; vice versa, individual
tumour markers may be associated with various
malignancies. Thus the use of multiple markers
based on the combination pattern for the selected
malignancy will improve sensitivity and specificity
of the detection.
Conclusion
The use of tumour markers in clinical oncology has
increased tremendously with rapid expansion of
techniques of detection and identification of new
markers in recent times, a trend that continues to

grow as technology progresses and our understanding
about our body and the disease processes increases.
However, such use is not without its pitfalls; in fact,
injudicious application of tumour markers is fraught
with risks of mistreatment (under-treatment or overtreatment) and its consequences. Of the numerous
tumour markers identified, described and extensively
researched upon, only a handful of them are used in
routine clinical practice; and even of these, only a
few have established consensus guidelines for use in
day- to-day care of patients.
Judicious application of tumour markers to clinical
practice needs a thorough understanding of the basics
of pathophysiology, the techniques of identification
or testing, reasons (in cases of both benign and
malignant tumours) for out-of-range levels of tumour
markers, as well as the knowledge of evidence of
their role in any given malignancy.

Role of Chemical Pathology in Screening and
Diagnosis of Multiple Myeloma
Dr Noreen Sherazi
Chemical Pathology

Multiple myeloma (MM) is characterized by the
neoplastic proliferation of a single clone of plasma
cells producing a monoclonal immunoglobulin.
Normally, plasma cells produce antibodies and
play a key role in the immune function. However,
uncontrolled growth of these cells leads to bone
pain and fractures, anemia, infections, and other
complications. In the United States, about four
people per 100,000 are diagnosed with MM each
year. The average age at diagnosis is 65 to 70 years.
The annual incidence of myeloma in the UK is
approximately 60-70 per million. Myeloma has a
higher incidence in Afro-Caribbean ethnic groups
than in Caucasians but there are few other distinctive
epidemiological features.
Criteria for Diagnosis — the Diagnosis of
Symptomatic MM requires the Following:



M protein in the blood or urine, plus
A bone marrow aspirate or biopsy showing that at least
10 per cent of the cells are plasma cells or the presence
of a plasma cell tumour (called a plasmacytoma), plus



Evidence of damage to the body as a result of
the plasma cell growth, such as high calcium in
the blood, renal failure, anemia or destructive
bone lesions (CRAB)

Investigation of a patient with suspected myeloma
should include the screening tests indicated followed
by further tests to confirm the diagnosis. We at
Clinical Chemistry department performing various
biomarkers for the screening and diagnosis of
multiple myeloma.
Screening Tests
Serum and urine protein electrophoresis
Among the laboratory methods available for the
separation of proteins, electrophoresis is a wellestablished and versatile technique widely used in
clinical chemistry. Protein electrophoresis of serum
and urine is a sensitive means of detecting the
abnormal monoclonal proteins found in myeloma.
The test can identify intact immunoglobulin or free
light chains in about 98 per cent of the cases.
9
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During electrophoresis of serum proteins, intact
monoclonal immunoglobulin molecules will migrate
as a sharply defined band. (Figure 1) This is called a

calcium of usually >0.25mmol/l above the upper
limit of normal or >2.75mmol/l and serum creatinine
of 1.9 mg/dl is suggestive of ROTI.
Tests to Establish Diagnosis
Immunofixation electrophoresis (IFE) of serum and
urine:
Identification of the immunoglobulin isotype
of a paraprotein by immunofixation of the
paraprotein band enables it to be classified as an
immunoglobulin G (IgG), immunoglobulin A (IgA)
or immunoglobulin M (IgM) molecule. (Figure 2)

Figure 1: Monoclonal Gammopathy on Serum Protein Electrophoresis
(AKUH Lab)

paraprotein, and is detected in about 80 per cent of
patients with myeloma. It is almost always found in
association with Bence-Jones protein in the urine.
Bence-Jones protein is a homogeneous kappa or
lambda free light chain.
In most of the remaining 20 per cent of cases of
myeloma where a paraprotein is not detected in the
serum electrophoretogram, monoclonal light chains
are readily detected by protein electrophoresis of
concentrated urine. This form of myeloma is usually
referred to as Bence-Jones myeloma.
Quantification of Non-Isotypic Immunoglobulins
Measuring total concentrations of IgG, IgA and
IgM in serum can reveal elevation of a specific
immunoglobulin isotype that is suggestive of the
presence of a paraprotein. However, the test does
not distinguish between the normal polyclonal
and abnormal monoclonal forms of a particular
immunoglobulin. This test is therefore not a
substitute for the serum electrophoretogram for
identifying the presence of a paraprotein in screening
for myeloma.
Serum Urea, Creatinine, Calcium & Albumin
Many patients with myeloma have myeloma-related
organ impairment (ROTI) in which corrected serum
10

Figure 2: Typing of Immunoglobulins on Immunofixation Electrophoresis
(AKUH Lab)

Other isotypes are extremely rare. The identity of
the isotype is important in differentiating whether
production of the paraprotein is by a clonal plasma
cell disorder, or by a clonal lymphoproliferative
condition.
IgG and IgA paraproteins suggest a clonal
plasma cell disorder. In myelomas which
produce paraproteins, IgG paraproteins occur in
approximately 75 per cent, and IgA paraproteins
in the remaining 25 per cent of cases. An IgM
paraprotein is extremely uncommon in myeloma.
It is more indicative of a clonal lymphoprolifer
ative disorder, such as low-grade non-Hodgkin’s
lymphoma. Waldenstrom’s macroglobulinaemia is
an example of one form of low-grade non-Hodgkin’s
lymphoma that is characteristically associated with a
serum IgM paraprotein.
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Tests to Estimate Tumour Burden and Prognosis
Quantification of Monoclonal Protein in Serum
and Urine
The serum paraprotein concentration can be used
for differentiating between the conditions.
Concentrations below the threshold value are
more likely to be monoclonal gammopathy of
uncertain significance and those above are more
likely to be myeloma. These values are IgG
paraprotein disorders 30 g/L and IgA paraprotein
disorders 20 g/L.
Patients with Bence-Jones myeloma have very
low serum concentrations of the protein.
However, they usually excrete more than 1 g of

Bence-Jones protein in a 24-hour collection of
urine.
ßeta-2 Microglobulin
Beta-2 microglobulin (B2M) is a useful tumour
marker for some blood cell cancers, for detecting
kidney damage, and for distinguishing between
glomerular and tubular disorders of the kidney. As
a tumour marker B2M test help to determine the
severity and spread (stage) of multiple myeloma
and may sometimes be ordered to evaluate the effectiveness of treatment. B2M has been associated
with tumour burden, the amount of cancer present,
and may be ordered to help evaluate the prognosis
of cancers such as leukemia and lymphoma.

1p/19q Deletion: Favourable Prognostic
Marker for Oligodendroglioma
Sony Siddiqui
Histopathology/Molecular Cytogenetics

Multiple chromosome abnormalities are reported in
solid tumours, but the major challenge has been to
separate critical and irrelevant events. Fluorescence
in situ hybridization has emerged as an extremely
important tool for detection and characterization of
nonrandom chromosome aberrations in cancer. FISH
results are utilized for a better understanding of the
biological behaviour of the tumour, and to assist in
determining the correct therapeutic approach.
Oligodendrogliomas is the third most common
glial neoplasm. It can grow in different parts of the
brain, but most commonly found in the frontal or
temporal lobes of the cerebrum. The frontal lobes
are responsible for cognitive thought processes
(knowing, thinking, learning, and judging). The
temporal lobes are responsible for coordination,
speech, hearing, memory, and awareness of time.
There are two types of oligodendroglioma: the
well-differentiated tumour, which grows relatively
slowly and in a defined shape; and the anaplastic
oligodendroglioma, which grows much more rapidly
and does not have a well-defined shape. Anaplastic
oligodendrogliomas are much less common than
well-differentiated oligodendrogliomas.

More common than either form of pure
oligodendroglioma is the mixed glioma, or
oligoastrocytoma. These mixed gliomas are a
mixture of oligodendroglioma and astrocytoma.
Role of 1p/19q as a Prognostic Marker
Among the various candidate biomarkers in gliomas,
the 1p 19q codeletion in oligodendroglioma
probably constitutes the best-characterized and
most extensively investigated marker up to date.
Loss of chromosome 1p and 19q is commonly
seen in Oligodendroglioma but is rare in other
tumour types, such as astrocytomas. The 1p/19q
deletion test is useful in tumours with a complex
“hybrid” morphology requiring differentiation
from pure astrocytomas to support the presence of
oligodendroglial differentiation/lineage.
FISH Assay
Specimens from biopsies, excisions or resections of
tumours received for FISH assay are handled as soon
as possible to preserve tissue morphology. Specimens
should be preserved in 10 per cent neutral-buffered
formalin (NBF), preferably as 3-4 mm blocks
11
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fixed for 18-24 hours followed by dehydration
and embedment in paraffin, for evaluation of 1p
and 19q deletions, tumour areas need to be preselected under the light microscope. Adequate areas
should contain more than 60 per cent of tumour cell
infiltration, and no necrosis or hemorrhage. FISH
analysis is performed using a dual-color approach
for chromosomes 1 and 19 separately. Target probes
hybridize to subtelomeric 1p36 and 19q13.3 in
combination with control probes on 1q and 19p,
respectively.

Interpretation
A normal, undeleted case will show two orange and
two green signals per cell while a deletion will have
only one orange signal and two green signals.

LSI1p36

Figure 2: FISH images show tissue sections, hybridized to 1p19q deletion probe. In images A and C orange signal is lost indicating deletion
of 1p and 19q respectively; Image B shows two orange and two green
signals indicating copies of both the chromosomes.
(AKUH Lab)

A

LSI 1p36 Region

Centromere

Telomere
EGFL3

TP73
LSI1q25

~400 kb

B

LSI 19q36 Region

1
Centromere

Therapy

Telomere
ZNF44

ZK1

MAN2B1

LSI 19p113

~500kb

LSI19q13

Figure 1: (A) shows target probe for 1p36; (B) shows
target probe for 19q13.
19

The assay is designed with one FISH probe for the
long arm of the chromosome (q) and a second probe
for the short arm (p).

12

Detecting 1p and 19q deletions are both
diagnostic and predict a favourable response
to therapy. Research has shown that anaplastic
oligodendroglioma patients who have a loss of
heterozygosity on chromosome 1p, or a combined
loss of heterozygosity on chromosomes 1p and
19q survive longer (an average of ten years), than
patients with tumours that lack these genetic changes
(an average of two years).

The standard treatment for all grades of
oligodendrogliomas is surgery to remove the tumour
completely. Oligodendrogliomas are among the only
brain tumours that can be successfully treated with
a type of chemotherapy called PCV (Procarbazine,
CCNU or lomustine, and Vincristine). Chemotherapy
is usually used only in cases of recurrent anaplastic
oligodendrogliomas. For patients with well-defined
oligodendrogliomas, median survival exceeds ten
years. For patients with anaplastic dendrogliomas,
median survival ranges from two to five years.
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EGFR Mutation Screening Test
Toheed Kausar
Molecular Pathology

Non-small cell lung cancer (NSCLC) accounts
for about 85 per cent of lung cancers and includes
predominantly adenocarcinomas (the most common
type) and squamous cell carcinomas.
Table: 1. Frequency of NSCLC in different types of lung
cancer

Type of Lung Cancer

Percent of NSCLC

Adenocarcinoma

40-50 per cent

Squamous

30-35 per cent

Large Cell

10-20 per cent

Significant progress has been made during the
last 20 years in the molecular characterization of
lung tumours. Mutational status in non-small-cell
lung cancer is critically important in determining
the most effective therapy. EGFR (Epidermal
Growth Factor Receptor), KRAS and EML4ALK (anaplastic lymphoma kinase) are fusion
genes; status for these biomarkers in NSCLC is
becoming an integral component in treatment
decisions.

Figure 1: Recurrent Mutations in NSCLC

Overall, KRAS mutations have been reported in
30–50 per cent of patients with adenocarcinoma
histology. Whereas the frequency of EML4ALK translocation ranges from 3 to 7 per cent in
unselected NSCLC.
EGFR Basics
EGFR (Epidermal Growth Factor Receptor) is
a cell-surface receptor tyrosine kinase, which
upon ligand binding leads to activation of
various downstream signaling pathways. EGFR
is linked to cell growth, proliferation, survival
and migration. Clinical studies have shown
that a subset of NSCLC patients harbors EGFR
mutations (Figure 2), and nearly 85 per cent
of those patients benefit from tyrosine kinase

Traditionally, non-small-cell lung cancers were
classified according to their histological features.
Various driver mutations have been associated
with these cancers over time. The mutations
are mutually
exclusive, as
shown in Figure 1
EGFR mutations
are found in 15 per
cent of cases from
North America,
Western Europe,
but are reported
in 30–50 per cent
of patients of East
Asian descent with
adenocarcinomas
with ronchoalveolar
features that
arise among
Figure 2: Important EGFR kinase domain mutations (exons 18 to 21)
non-smokers.
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inhibitors (TKI) therapy. Furthermore, EGFR
mutations are found associated with response
to gefitinib and erlotinib TKI, and prolonged
survival in NSCLC patients.
EGFR Mutation Analysis
The Molecular Pathology Section, The Aga Khan
University Hospital Clinical Laboratory, AKUH
accepts formalin fixed paraffin embedded tissue
(FFPET) blocks for EGFR mutational analysis.
Briefly, genomic DNA extracted from FFPET
section is PCR amplified using in Real Time PCR
chemistry (Figure 3). The assay can detect 41

Figure 3: Workflow of EGFR Mutation Analysis Protocol.

different mutations in four exons (18-21) of EGFR
gene including several point mutations, deletions and
insertions. Currently, EGFR is validated for biopsies
of NSCLC.
Significance of EGFR Mutation Analysis
The prevalence of EGFR mutations in unselected
cases of NSCLC is approximately 10 per cent.
The clinical responses to TKI were shown to be
associated with EGFR mutations. However these
mutations occur most frequently, but not exclusively,

14
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in non-smoking/ light-smoking female patients of
Asian ancestry with adenocarcinoma histologies.
Clinical data indicate that patients with advanced
NSCLC tumours harboring activating mutations
of EGFR, which occur most commonly as
deletions in exon 19 or as the L858R point
mutation in exon 21, exhibit a high response rate
and prolonged progression-free survival (PFS)
when treated with anti-EGFR TKIs, both in firstand second-line therapy. Other less common
EGFR mutations, such as G719X substitutions in
exon 18 and the L861Q point mutation in exon
21 also predict for responsiveness to anti-EGFR
therapies. Median survival in patients with EGFRmutant NSCLC treated with antiEGFR TKIs is now approximately
two years.
But some patients would
eventually develop resistance to
these TKIs. Subsequent studies
found that a secondary mutation in
the EGFR gene (T790M mutation)
could be the main resistance
mechanisms involved. T790M
mutation, which is thought to
cause steric hindrance and impair
the binding of gefitinib/erlotinib. The T790M is
present as a minor allele before TKI therapy and
accounts for about half of the acquired resistant
cases.
The future of molecular testing and adoption of
personalized treatments in NSCLC would depend
upon identification of new biomarkers and their
potential inhibitors. In addition, implementation
of routine testing of known biomarkers associated
with specific treatments (EGFR, ALK) and our
understanding for causes of tumour resistance would
create resource for novel therapeutic strategies.
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Clinical Utility of BCR-ABL1 Kinase Domain
Mutational Analysis
Nazneen Islam
Molecular Pathology

Introduction
The frequency of mutation is found to be much
higher in the acute phase/blast crisis phase as
compare to chronic phase.
Imatinib resistance due to BCR-ABL1 Kinase
Domain mutations may arise through a variety
of mechanisms. The most common cause of
resistance is a conformational change in protein
which results from mutation in Kinase Domain
drug binding site specifically P-loop or ATP
binding region.

Chronic myeloid leukemia (CML) is a chronic
hematopoietic stem cell disorder characterized
by extensive proliferation and expansion of
myeloid cells at varying stages of maturation and
differentiation. The Philadelphia (Ph) chromosome
(Figure1) is a hall mark of CML and results from

Types of BCR-ABL1 Kinase Domain Mutations
To date about ninty different mutations (Table
2) in Kinase Domain which are associated with
Graph 1. Frequency of different BCR-ABL kinase Domain
Mutation

the reciprocal translocation between nine and twenty
two, creating a fusion gene consisting of break point
cluster region and Abelson proto-oncogene (BCRABL) with constitutive tyrosine kinase activity
resulting in myeloid proliferation.
Imatinib mesylate (Glivec) is currently the standard
of care for CML. Glivec is a tyrosine kinase inhibitor
(TKI) which induces durable responses in the
majority of CML patients. The overall survival of
CML patients with complete cytogenetic response
is reaching up to 85 per cent at end of seven year’s
follow-up period.
Mechanism of Imatinib Resistance
Lately, imatinib resistance has become a
significant problem in the management of CML
patients. Mutations in the BCR-ABL1 Kinase
Domain gene are the most commonly reported
mechanism of acquired resistance to imatinib
leading to shortened survivals of CML patients.

Frequency

Figure 1: Chromosomal Translocations t (9; 22) (q34; q11.2)

resistance to TKI have been identified. Mostly
mutations are clustered within nine amino acid
positions on KD genes including T315I, Y253H/F,
M351T, G250E, E255K/V, F359V, and H396R.
Some of these mutations are found to result in
resistance to Imatinib and also second line TKIs
such as Dasatinib and Nilotinib. For example, the
T315I mutation is the most common KD mutation
associated with resistant to all generation of
TKI therefore screening for T315I mutation is
recommended for all CML patient undergoing
treatment.
15
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Molecular uL/uu/LL Based Diagnosis for BCRABL Kinase Domain Mutations
The Molecular Pathology section, Clinical
Laboratories, AKUH offer DNA sequencing for the
detection of BCR-ABL Kinase domain mutations
(Figure 3). In this method RNA is extracted and
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subjected to PCR amplification using primers that
amplify 716 bp regions of KD gene resulting in
the formation of a specific PCR product. The PCR
product is sequenced using an automated capillary
electrophoresis DNA sequencer and the resulting
nucleotide sequence is analyzed for the presence
of mutations using the Mutation Surveyor software
(SoftGenetics, USA).
When to Look for BCR-ABL1 Kinase Domain
Mutations
Summary of cases in which BCR-ABL kinase
Domain mutation analysis is recommended

Figure 3: Detection of BCR-ABL kinase domain mutations by direct DNA
sequencing.

converted to complementary DNA using a reverse
transcriptase enzyme. Complementary DNA is

At Diagnosis
Only in acute phase/blast crisis phase
During First Line Imatinib Therapy
In case of failure
In case of major molecular response loss
In case of suboptimal response
During second Line Dasatinib or Nilotinib Therapy
In case of hematologic and cytogenetic failure

Utility of Wilms’ Tumour Expression in
Minimal Residual Disease
Dr Zeeshan Ansar Ahmed and Samina Ghani
Molecular Pathology

In acute myeloid leukemia (AML), various
approaches have been used to characterise
minimal residual disease (MRD) such as,
immunophenotyping, cytogenetic and molecular
analysis. Unfortunately, the methods with higher
sensitivity (i.e. molecular based tests) may be
hampered by the lack of a specific target marker.
A majority of AML cases, do not have a specific
cytogenetic and ⁄ or molecular alteration that can
be used as a reliable or appropriate marker of
MRD after morphological remission. The Wilms’
tumour gene (WT1) was first cloned in 1990.
During embryogenesis the WT1 gene encodes
a protein which plays a critical role in normal
development of the kidney, gonads, spleen and
heart. It also identified as an onco-suppressor
gene which encodes a transcription factor that
plays a fundamental role in the development of
Wilms’ tumour. Moreover, it is now evident that
WT1 gene values correlate with disease status,
16

thus being a good candidate for the evaluation
of MRD, especially in the relevant percentage of
patients who lack a specific molecular marker of
their disease.
The WT1 gene is present on chromosome 11p13q
and consists of 10 exons. It encodes a transcription
factor that required for normal cellular development
and cell survival. This gene is highly expressed in
several hematopoietic malignancies for example
acute myeloid leukemia, acute lymphoblastic
leukemia, chronic myeloid leukemia in blast crisis,
myelodysplastic syndrome and lymphomas. It
also over expressed in various other types of solid
tumours likes melanoma, lung, breast, testicular and
ovarian cancers.
In the majority of adult patients with leukemia it is
possible to achieve a complete remission (CR). In
the case of AML, 60-80 per cent of patients reach CR
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however; the majority of these patients subsequently
relapse. Currently, there is an effort to predict relapse
by MRD and subsequently to begin the treat¬ment
during clinical and hematological remission prior to
overt hematological relapse. Treatment of MRD has
a greater probability of success, is less distressing
for the patients and also has a lower cost than the
treatment of a probable hematological relapse.
Consequently, the WT1 gene is a suitable candidate
as a marker for monitoring MRD in AML, either
in bone marrow or in PB, particularly in patients
without specific molecular markers.
The molecular techniques, based on an analysis of
nucleic acids, appear to be most useful for MRD
monitoring. Molecular techniques are highly
specific and in connection with polymerase chain
reaction (PCR) also very sensitive. These techniques
enable the detection of a prolifera¬tion of the
leukemic clone weeks or several months prior
to the hematological relapse, when the patient is
still in hematological and clinical remission. The
appropriate marker for MRD monitoring should
be over expressed minimally two logs higher in
diagnostic samples compared to those from normal
healthy individuals. Therefore, estimation of the
level of the WT1 expression could be beneficial
for predicting hemato¬logical relapse. As the WT1
gene is often expressed in patients in permanent
remission, it was necessary to establish an upper
remission limit which, when exceeded, signals a
high risk of hematological relapse. In fact, the upper
remission limit defines the molecular relapse level.
However, a persistently elevated WT1 level
following therapy is predictive of poor outcome.
In addition, it has been demonstrated that normal
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hematopoietic recovery following chemotherapy
does not significantly modulate WT1 expression
levels. Monitoring of disease status with WT1
affords the opportunity to include more AML
patients in a single assay than any other leukemic
marker and has a potential role in MRD monitoring
of patients that are cytogenetically normal.
Method for detection of WT1 expression
For WT1 analysis, RNA is extracted from peripheral
blood or bone marrow of diagnosed cases of AML
and complementary DNA is synthesized. This cDNA
is used for PCR using specific primers to the WT1
gene along with standards and controls to determine
WT1 expression.

Figure 1. Differential WT1 expression in AML cases as compared with
healthy controls. Relative expression of the WT1 gene in peripheral
blood of normal healthy donors and AML patients at diagnosis. The bars
represent medians and the boxes represent 25th to 75th percentiles of
WT1 expression.

Cytogenetic Testing for Acute Myeloid Leukaemia
Marium Ghani
Histopathology/Molecualr Cytogenetics

Acute myeloid leukaemia (AML) is a type of
cancer that affects immature blood cells on the
myeloid cell line leading to neutropenia, anemia,
and thrombocytopenia. Differentiation and
treatment of acute leukaemias require specialist
techniques including cytochemical staining,
immunophenotyping and chromosome studies
(cytogenetics).

Laboratory Tests used to Diagnose Acute Myeloid
Leukaemia
One or more of the following lab tests may be done
on the samples to diagnose AML and/or to determine
the specific subtype of AML.

17
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Morphology: Blood and marrow smears are
morphologically examined using a MayMay-Grünwald-Giemsa or a Wright-Giemsa stain.
Immunphenotying: Multiparameter (commonly at
least three to four color) flow cytometry is used to
determine lineage involvement of a newly diagnosed
acute leukemia.
Conventional cytogenetics: Conventional
cytogenetics analysis is a mandatory component in
the diagnostic evaluation of a patient with suspected
acute leukemia. A minimum of 20 metaphase cells
are analyzed from bone marrow/ blood which is
considered mandatory to establish the diagnosis of
a normal karyotype, and recommended to define an
abnormal karyotype.
Molecular cytogenetics: Methanol/acetic acid–
fixed cell pellets should be stored so if cytogenetic
analysis fails, fluorescence in situ hybridization
(FISH) is an option to detect gene rearrangements,
such as RUNX1-RUNX1T1, CBFB-MYH11, MLL
and EVI1 gene fusions, or loss of chromosome 5q
and 7q material. FISH analysis
has several advantages over
Risk Group
chromosome studies. It has a
rapid turnaround time, detects
Favorable
small numbers of abnormal cells,
and can also be performed on
non-dividing (interphase) cells.
It can detect cryptic or subtle
Intermediate
rearrangements that might be
difficult to detect by routine
karyotyping. In addition, FISH is
frequently necessary to identify
MLL fusion partners in 11q23
translocations.
Adverse

soluble (IDH1) gene can be useful in certain
circumstances.
Genome-wide studies: Recent progress in genomics
technology has resulted in the identification of
novel genetic abnormalities and holds the promise
of making the systematic characterization of cancer
genomes feasible. It includes gene- and microRNAexpression profiling and single nucleotide
polymorphism (SNP)-based mapping arrays.
Prognostic Information for Patients with Acute
Myeloid Leukaemia
The outcome for patients with AML depends on
a variety of factors including age of the patient,
intensity of postremission therapy, biologic
characteristics of the disease and the most important
of which are the cytogenetics at presentation.
Results of cytogenetic analysis at diagnosis provide
important prognostic information in AML and aids in
monitoring response to therapy or progression of the
disease. Following are the cytogenetics risk groups
which can be found in patients with AML:
Abnormality

Comment

t(8;21) t(15;17) inv(16)

Whether alone or in
conjunction with other
abnormalities.

Normal +8 +21 +22 del(7q)
del(9q) Abnormal 11q23 All
other structural/numerical
abnormalities

ie, Cytogenetic abnormalities not classified as favorable or adverse. Lack of additional favorable or adverse
cytogenetic changes.

−5 −7 del(5q) Abnormal
3qComplex

Whether alone or in conjunction with intermediaterisk or other adverse-risk
abnormalities.

Molecular genetics: Molecular
diagnosis by reverse
transcriptase–polymerase
Ref: Grimwade et al, Blood 1998;92:2322-2333
chain reaction (RT-PCR) for the
recurring gene fusions, such as RUNX1-RUNX1T1,
AML Panel by FISH Offered by the Clinical
CBFB-MYH11, MLLT3-MLL, DEK-NUP214, and
Laboratory
somatically acquired mutations in several genes,
for example, the NPM1 gene, the FLT3 gene, the
For FISH testing, a sodium-heparin (green-top) tube
CEBPA gene, myeloid/lymphoid or mixed-lineage
with 3–4 ml of blood/ bone marrow is required.
leukemia (MLL) gene, the neuroblastoma RAS viral
Samples should be stored at room temperature and
(v-ras) oncogene homolog (NRAS) gene, the Wilms
transported to the laboratory within 24 hours of draw.
tumour 1 (WT1) gene, the v-kit Hardy-Zuckerman
Bone marrow cells on unstimulated cultures either
4 feline sarcoma viral oncogene homolog (KIT)
from direct harvest or 24 hour culture are analyzed
gene, runt-related transcription factor 1 (RUNX1)
by FISH using a set of commercially available FISH
gene, the tet oncogene family member 2 (TET2)
probes (Vysis, Abbott). Each probe can be run as a
gene, and the isocitrate dehydrogenase 1 (NADP+),
part of the panel or individually. Following are the
18
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FISH probes available at the cytogenetics laboratory
of the AKUH and can be requested for AML:
t(8;21): AML with t(8;21)(q22;q22) is seen most
often in patients with M2 and is defined by the
presence of this translocation, a variant translocation,
or molecular RUNX1-RUNX1T1 fusion.
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both de novo and therapy related AML. It is also
seen as monosomy five. In AML, 5q deletion is
usually associated with a complex karyotype. The
most commonly observed interstitial deletions are
del(5)(q13q31), del(5)(q13q33), and del(5)(q22q33),
forming a commonly deleted region (CDR) at
5q31-q32.

t(15:17): AML with t(15;17)(q22;q21)/PML-RARA
is a distinct clinicopathologic entity defined by the
presence of the PML-RARA fusion and is seen most
often in patients with M3 (Figure 1 and Figure 2).
t(11q23:var): AML with t(9;11) is seen in patients
with M0-M7 subtypes and is the only translocation
involving the MLL gene included as a distinct
biologic subtype. Although >60 fusion partner
genes are known for MLL, the more common
translocations in AML include 6q27 (MLLT4), 10p12
(MLLT10), 19p13.1 (ELL), and 19p13.3 (MLLT1),
all resulting in fusion genes.

Figure 1: G-banded karyotype with t(15;17)(q22;q21) at arrows (Wakim
et al. 2012).

inv(16): AML with inv(16)/t(16;16) is seen most
often in patients with M4 and is defined by the
translocation and/or molecular fusion of CBFB and
MYH11.
+8: Trisomy eight in AML occurs in patients with
M0-M7 subtypes either as the sole anamoly or
together with other clonal chromosome abberations.
-7/7q deletion: is frequent in secondary MDS
or AML, and also in leukemias occurring in
individuals with constitutional syndromes including
predisposition to myeloid disorders.
-5/5q deletion: Deletion of 5q can be observed in

Figure 2: Dual-color Dual-fusion translocation probe for the detection
of PML-RARA fusion. Panel A shows a normal FISH pattern (2R, 2G),
whereas panel B reveals fusion of the PML and RARA loci at arrows.
(Clinical Laboratory)

Diffuse Large B-Cell Lymphoma Subgroups
have Different Phenotype
Dr Shahid Pervez & Dr Arsalan Ahmed
Histopathology,

Diffuse large B-cell lymphoma is the most
common lymphoma subtype, accounting for 30
per cent of all non-Hodgkin’s lymphomas (NHL).
It shows an aggressive clinical course, and
comprises a heterogeneous group of lymphomas
in terms of morphology, immunophenotype and
molecular abnormalities.

DLBCL, NOS includes three common
morphologic variants (centroblastic,
immunoblastic and anaplastic) plus rare
morphologic variants. These variants are
important for pathologist to recognize so they
are not misdiagnosed as either indolent or
lymphoblastic lymphomas.
19
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DLBCL can also be divided based on cell of
origin. The WHO lists two molecular and IHC
subgroups: Germinal center-like (GCB) and
non-germinal center-like (non-GCB) subgroups.
Gene-expression profiling studies have
distinguished three molecular subtypes of DLBCL
known as ‘‘germinal center B-cell-like’’ (GCB),
‘‘activated B-cell-like’’ (ABC), and ‘‘primary
mediastinal B-cell lymphoma’’ (PMBL). GCB
DLBCLs seem to arise from normal germinal
center B cells, ABC DLBCLs may arise from

postgerminal center B cells that are arrested
during plasmacytic differentiation, and PMBLs
may arise from thymic B cells.
Since gene expression profiling (GEP) has
remained as an impractical clinical tool, a number
of immunohistochemical algorithms have been
proposed to translate GEP classification into
a manageable set of measurable proteins to
distinguish between GCB and non-GCB type
DLBCL. (Figure 1)

Figure 1: Four immunostaining algorithms used to assess differentiation profile (GCB vs non-GCB) in patients with DLBCL.
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The best know is “Hans algorithm”. According to
this algorithm, GC group is CD10+ and/or BCL6+,
MUM-1-. The non-GCB group is CD 10-, BCL6+,
MUM1+ or CD10-, BCL6-. There are some unresolved issues attached to this algorithm. First, not
everyone interprets the GC group in the same way.
According to some, both CD10 and BCL6 should
be positive, while some believe either is fine, but
MUM1 and CD138 should be negative. Secondly
not everybody will find that GCB group does better
than non-GCB group. (Figure 2)

A

C

Figure 2: (A): Diffuse Large B-cell Lymphoma (DLBCL) (H&E), (B)
DLBCL stained with anti-CD10 antibody with strong diffuse cytoplasmic
staining consistent with ‘Germinal Centre (GC) phenotype’, (C) DLBCL
stained with anti-Bcl6 antibody showing strong nuclear staining
consistent with GC phenotype, (D) DLBCL stained with anti-MUM1
antibody showing strong diffuse nuclear staining consistent with ‘PostGerminal Centre phenotype. (Courtesy: AKUH Lab)

This algorithm, however, was designed for use
in patients treated with CHOP without rituximab
(pre-rituximab era), and in addition, it had low
concordance with GEP analysis (71 per cent for
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GCB, 88 per cent for non-GCB). The prognostic
relevance of the Hans algorithm led to inconsistent
results in subsequent studies performed in patient
groups treated with R-CHOP. Nevertheless, the
Lymphoma/Leukemia Molecular Profiling Project (L/
LMPP) has demonstrated the GCB group still does
better than the non-GCB group in the “R-CHOP”
era. The literature remains inconsistent and
indecisive. Some studies have shown that the GCB
group did better than the non-GCB group when
CHOP therapy was used but no differences could
be seen with R-CHOP, while some have
reported that GCB did no better than nonGC group after treatment with R-CHOP.
Others have reported no differences even in
the CHOP era. There is a newer algorithm
(Choi and coworkers) that compared to the
their Hans algorithm improves concordance
with the gene expression profiling data from
86 per cent to 93 per cent using GCET1
and FOXP1 antibodies in addition to CD10,
BCL6 and MUM1.
Newer algorithms have also been
proposed which include Tally algorithm
and the latest algorithm was proposed
in International DLBCL RituximabCHOP Consortium Program Study. This
latter algorithm boasts to have a simpler
structure than other recently proposed
algorithms and is based on the expression of
CD10, FOXP1, and BCL6 and has a 92.6 per cent
concordance with GEP.
Others who recently tested multiple algorithms
suggest that none work and what you really need are
gene expression profiling studies, unfortunately an
impractical suggestion. In the end we believe that
more work has to be done in this field and that one
should still be careful in using these algorithms for
determining prognosis between GCB and non-GCB
DLBCL subgroups.
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Meeting Report: 1st Joint Conference of PAP/
Societies of Pathologists and 36th Annual
Conference Pakistan Association of Pathologists
Reported by Dr Hafsa Majid
Resident, Chemical Pathology

The 1st Joint Conference of Pakistan Association
of Pathologist (PAP) and Societies of Pathologists
was held in Islamabad from 7th - 9th Dec 2012.
This conference was hosted by Armed Forces
Institute of Pathology (AFIP) at the Convention
Centre Islamabad. The conference excelled in
presenting exciting developments in the field
of pathology and laboratory medicine; some of
the highlights are reported here. Preconference
workshops of Histopathology, Haematology,
Microbiology, Chemical Pathology and
Immunology were conducted by the hosting
institute. The goal was to facilitate participants
in exploring new areas in respective fields at an
interactive learning forum.
Pathologists, trainees and laboratory personnel
from all over Pakistan and abroad attended
this conference. The first day began with
inauguration ceremony on evening of 7th
December followed by the ‘Razi lecture’, given
by Professor Aw Tar Choon, from Singapore
on ‘Clinical application of circulation tumor
cells’. Jabir Ibn Hayyan lecture was given by
Dr DP Mikhailidis from United Kingdom, who
highlighted on cardiovascular risk assessment
and emphasized on utility of risk prediction
tools. Evening ended with a banquet dinner and
Mehfil-e-Hamd o Naat.
Second day December 8, 2012 started with Ibn-eSina lecture given by Prof Dr Lawrence Faulkner
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from United Kingdom on role of international
NGOs to improve access to cure and prevention
of hemoglobinopathies in developing countries,
followed by plenary state-of-the-art lectures
delivered by eminent pathologists from United
Kingdom. Guest speakers talked on range of
topics from organ transplant, DNA testing to paper
publication, which generated exciting discussions.
These lectures were followed by plenary lectures in
different disciplines of pathology given by Aga Khan
University (AKU) faculty and other pathologists
from Pakistan. Parallel scientific sessions of free
papers gave participants including a large number
of AKU residents great learning opportunity by
sharing work on a national platform. Several selected
abstracts were also displayed as posters which
portrayed research advances in the field of pathology.
The scientific sessions were followed by banquet
dinner.
The Third day conference was held at Barian, Murree.
Day started by meet the experts’ sessions, a great
learning opportunity for budding pathologists for
learning from experts in their respective fields. This
was followed by plenary sessions. The conference
closing ceremony was in afternoon followed by a
marvelous meal and lively social discussion. It was a
wonderful way to finish the conference. Like always
the conference was successful in bringing together
delegates from the different disciplines of pathology
and laboratory medicine and allowing opportunity for
a healthy debate.
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Pathology and Microbiology Research Day
2012
Dr. Hafsa Majid
Resident, Chemical Pathology

The first Pathology and Microbiology Research
Day of Aga Khan University Hospital was held
on October 11, 2012 at Pearl Continental Hotel,
Karachi. This event showcased original research
studies from residents and faculty of Department of
Pathology and Microbiology.
The programme started with recitation from Holy
Quran, welcoming address was given by the
department’s Chair Dr Naila Kayani followed by an
introductory speech given by Chair of research day’s
organizing committee, Dr M. Asim Baig. Residents,
staff and junior faculty from all sections of Pathology
and Microbiology shared their research work with
their fellow trainees, faculty and other investigators
via presentation of free papers and poster session.
Renowned scientist of Pakistan Dr Atta-ur- Rahman
was invited as guest speaker, who gave an enlighting
talk on developments in the field of research in
Pakistan. This was followed by a talk given by
Dean, Research and Graduate Studies AKU, Dr
El-Nasir Lalani on need of developing research
activities to help us achieve the challenges posed by

Pathology Research Day 2012

accelerating scientific changes. Final address was
by Dean, Medical College AKU, Dr Farhat Abbas
who highlighted that the importance is not only to
do research but also to get that research out to the
scientific community. He also congratulated the
organizers of the event for arranging a platform that
provided the opportunity to budding researchers to
present their work to a large scientific community.
The program ended with certificate distribution and
the participants were then provided the opportunity
to interact with each other and the guests during dinner.
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